louisakewell, Author at European Medical Journal - Page 135 of 153

Fundamental Principles of Raising an Antitumour Immune Response in Vivo: A Complex Model, a Case Report, and a Perspective

In preclinical model systems, the fundamental principles underlying a successful and durable anti-tumour immune response are well demonstrated.

Immunotherapy of Cancer: Towards a New Era

In the past two decades, immunotherapy of cancer has developed into an established treatment option. At first, the development of monoclonal antibodies…

Radiotherapy for Breast Cancer: How Can it Benefit from Advancing Technology?

There have been significant technological and technical advances in radiotherapy over the last 20 years. This paper presents the pertinent advances and…

Management of Patients with High-Grade Glioma

The scientific basis for the surgical management of patients with glioma is rapidly evolving. The infiltrative nature of these cancers precludes a…

State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer

Prostate cancer (PrCa) is the most common cancer type in men in developed countries. In the last few years, a dramatic change has occurred in the…

EMJ

The Oncotype DX® Test and Precision Oncology: New Data Presented at ESMO Further Demonstrate Genomic Health’s Successful Approach to Understanding Tumour Biology

GENEVA, Switzerland, [September 29, 2014] — In line with this year’s theme for the annual European Society for Medical Oncology (ESMO) Congress…

EMJ

ESMO Announces 15 New Designated Centres of Integrated Oncology and Palliative Care

Lugano, 19 September 2014 – Gaps in palliative care for cancer patients are revealed in new research to be presented later at the ESMO 2014 Congress…

EMJ

ACCA Congress: Ensuring a Rapid Response to Cardiac Emergencies

Monday 16 September 2014 Sophia Antipolis, France – Acute cardiovascular care is the specialty of cardiology dealing with acute problems in need of…

EMJ

European Commission Grants Marketing Authorisation for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukaemia and Follicular Lymphoma

Foster City, CA, 19 September 2014 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing…

Biosimilars in Hematology: Increasing Choice, Expanding Access

Biologicals have revolutionised modern medicine by offering vital therapeutic options to treat or prevent complex, disabling, and life-threatening diseases.